Takahiro Motoki

Takahiro Motoki

Auto-generated profile, based on publicly available information

Takahiro Motoki

Department of Pharmacy, Kagawa University Hospital

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Neuromuscular Disorders
Verified
Journal Article
Closed access
TMTakahiro Motoki
Takahiro Motoki
YSYuko Shimizu-Motohashi
Yuko Shimizu-Motohashi
HKHirofumi Komaki
Hirofumi Komaki
MMMadoka Mori-Yoshimura
Madoka Mori-Yoshimura
YOYasushi Oya
Yasushi Oya
MSMasayuki Sasaki
Masayuki Sasaki

10 June 2020 in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Verified
Journal Article
Open access
PDF file
TTTatsuya Tai
Tatsuya Tai
KYKazunori Yamaguchi
Kazunori Yamaguchi
MWMasahiro Watanabe
Masahiro Watanabe
TITatsuya Inoue
Tatsuya Inoue
TMTakahiro Motoki
Takahiro Motoki
HHHitoshi Hochi
Hitoshi Hochi
To evaluate changes in the efficacy and safety of antimicrobial therapy through de-escalation improved by the antimicrobial stewardship (AS) activities, which started from 2013 in Kagawa University Hospital, we analyzed changes in the de-escalation rate and the patient outcomes. The number of carbapenem-treated cases evaluated as ‘improper use’ had decreased from 2013 to 2017. In most of these cases, improper use of blood culture was indicated. The AS team directed the proper use of carbapenem through weekly rounds, focusing on “intervention and feedback” according to the guideline. This activity was performed with emphasis on the appropriate use of blood culture results and the process of target therapy. As a result, it was shown that the number of blood culture orders and the rates of hospitalized cases, for which multiple sets of blood cultures were ordered, were increased. Also, the de-escalation rate of blood culture-positive cases treated with carbapenem was improved from 13.1% in 2011 to 29.9% in 2017. Furthermore, as a patient outcome, the 90-day mortality rate was decreased from 24.3% in 2011 to 15.6% in 2017. Similarly, the recurrent bloodstream infections rate was decreased from 5.6% to 0%. On the other hand, in 2011 vs 2017, there was no significant difference in the detection rate of resistant bacteria. Taken together, most of the changes in the indicators related to patient outcome analyzed in the present study suggest that AS activities improved the de-escalation rate, and that the de-escalation contributed to the efficacy and safety of antimicrobial therapy.

15 December 2013
Verified
Conference Paper
Closed access
TIT Iwamoto
T Iwamoto
JMJ Matsuoka
J Matsuoka
TNT Nogami
T Nogami
TMT Motoki
T Motoki
Tadahiko ShienTadahiko Shien
Tadahiko Shien
LPLajos Pusztai
Lajos Pusztai
Purpose: We examined Estrogen receptor (ER) mRNA expression and molecular subtypes in breast cancers that are Progesterone receptor (PR) positive but ER negative by immunohistochemistry (IHC) to assess if these cancers molecularly resemble true ER positive cancers. Patients and Methods: Patients were those with newly diagnosed ERBB2-negative breast cancer treated with neoadjuvant chemotherapy containing sequential taxane and antheracycline-based regimens (then endocrine therapy if ER-positive by IHC). ER and PR status was determined by IHC in 501 primary breast cancers in routine pathology laboratory. Gene expression profiling was done with the Affymetrix U133A gene chip (Gene Expression Omnibus number: GSE25066). We compared expressions of ESR1, MKI67 mRNA and molecular subtypes determined by the PAM 50 classifier between IHC-ER-positive/PR-positive (n = 223), ER-positive/PR-negative (n = 73), ER-negative/PR-positive (n = 20), and ER-negative/PR-negative (n = 185) cancers. We also plotted survival curves by ER and PR status based on IHC. Results: ER or PR positivity by IHC was defined ≥ 1% staining. ER positivity by ESR1 mRNA expression was defined as > 10.18 previously published. Among the IHC-ER-negative/PR-positive, ER-positive/PR-negative, and both ER/PR-positive, and ER/PR-negative patients, 25%, 79%, 96% and 12% were positive by ESR1 mRNA expression, respectively. The average ESR1 expression was significantly higher in the ER/PR-positive and ER-positive/PR-negative cohorts compared with the ER-negative/PR-positive or ER/PR-negative cohorts. The average MKI67 mRNA expression was significantly higher in the ER-negative/PR-positive and ER/PR-negative cohorts. Among the ER-negative/PR-positive patients, 15% were luminal A, 5% were Luminal B, and 65% were basal like; among the ER-positive/PR-negative patients, 59% were luminal type. The relapse free survival rate of ER-negative/PR-positive patients was equivalent to ER/PR-positive or ER-positive/PR-negative, and significantly better than that of the ER-negative/PR-negative cohort. Conclusion: Only 20-25% of the ER-negative/PR-positive tumors show molecular features of ER-positive cancers (i.e high ER mRNA expression and luminal molecular class). These cancers also have higher proliferation rate than ER-positive cancer. However, the survival of these cancers with only chemotherapy is similar to ER-positive cancers with chemotherapy and endocrine therapy, and is better than ER-negative cancers. The contribution of endocrine therapy to this good outcome is to be invested in the future. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-05-09.